Glaucoma: Present challenges and future trends

Ophthalmic Research

Volumn 50, Issue 4, 2013, Pages 197-208

  Bettin, Paolo ^a   Di Matteo, Federico ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Detection; Genetics; Glaucoma; Medical treatment; Surgery

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID 1 RECEPTOR; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYANOCOBALAMIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DAPIPRAZOLE; FATTY ACID; LATRUNCULIN B; MELATONIN; MEMANTINE; METALLOPROTEINASE; MIOTIC AGENT; MITOMYCIN; MYOCILIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPTINEURIN; PALMIDROL; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; RHO KINASE INHIBITOR; TIMOLOL;

AQUEOUS HUMOR FORMATION; AQUEOUS HUMOR OUTFLOW; CATARACT EXTRACTION; CATARACTOGENESIS; CLOSED ANGLE GLAUCOMA; CONJUNCTIVAL HEMORRHAGE; CONTACT LENS; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EARLY DIAGNOSIS; EYE BLOOD FLOW; FILTERING OPERATION; GENETIC ASSOCIATION; GENICULATE BODY; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANT; GLAUCOMA SURGERY; HUMAN; HYPEREMIA; HYPERSENSITIVITY; HYPERTRICHOSIS; INTRAOCULAR PRESSURE; IRIDOTOMY; IRIS DISEASE; LETHARGY; LONG TERM CARE; LOSS OF APPETITE; MASS SCREENING; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); METAL STENT; MIOSIS; MYOPIA; NEPHROLITHIASIS; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULOPLETHYSMOGRAPHY; OPEN ANGLE GLAUCOMA; OPHTHALMIC DIODE LASER; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PARESTHESIA; PATIENT COMPLIANCE; PATIENT EDUCATION; PHACOEMULSIFICATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIGMENT DISORDER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PSEUDOEXFOLIATION; PUNCTAL PLUG; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULOPATHY; REVIEW; SCANNING LASER OPHTHALMOSCOPY; SCANNING LASER POLARIMETRY; SIDE EFFECT; STEREOSCOPIC VISION; TRABECULECTOMY; TRABECULOPLASTY; UNSPECIFIED SIDE EFFECT; VISION TEST; VISUAL ACUITY; VISUAL CORTEX; VISUAL IMPAIRMENT; HEALTH STATUS; HEREDITY; TREND STUDY; VISCOCANALOSTOMY;

ANTIHYPERTENSIVE AGENTS; EARLY DIAGNOSIS; GENETIC PREDISPOSITION TO DISEASE; GLAUCOMA; HUMANS; MASS SCREENING; OCULAR HYPERTENSION; OPHTHALMOLOGIC SURGICAL PROCEDURES;

EID: 84888266074     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000348736     Document Type: Review

References (106)

1. Resnikoff S, Pascolini D, Etya'ale D, et al: Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82: 844-851. (Pubitemid 39573742)
2. Quigley HA: Glaucoma. Lancet 2011; 377: 1367-1377.
3. Quigley HA, Broman AT: The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267. (Pubitemid 43325451)
4. Varma R, Lee PP, Goldberg I, Kotak S: An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol 2011; 152: 515-522.
5. Deva NC, Insull E, Gamble G, Danesh-Meyer HV: Risk factors for first presentation of glaucoma with significant visual field loss. Clin Experiment Ophthalmol 2008; 36: 217-221. (Pubitemid 351560269)
6. Buys YM, Gaspo R, Kwok K: Referral source, symptoms, and severity at diagnosis of ocular hypertension or open-angle glaucoma in various practices. Can J Ophthalmol 2012; 47: 217-222.
7. Vaahtoranta-Lehtonen H, Tuulonen A, Aronen P, et al: Cost effectiveness and cost utility of an organized screening programme for glaucoma. Acta Ophthalmol Scand 2007; 85: 508-518. (Pubitemid 47163112)
8. Nayak BK, Maskati QB, Parikh R: The unique problem of glaucoma: under-diagnosis and over-treatment. Indian J Ophthalmol 2011; 59(suppl 1):S1-S2.
9. Mowatt G, Burr JM, Cook JA, et al: Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis. Invest Ophthalmol Vis Sci 2008; 49: 5373-5385.
10. Burr JM, Mowatt G, Hernandez R, et al: The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-190.
11. Siddiqui MA, Azuara-Blanco A, Burr J: The quality of reporting of diagnostic accuracy studies published in ophthalmic journals. Br J Ophthalmol 2005; 89: 261-265. (Pubitemid 40327603)
12. Tuulonen A: Cost-effectiveness of screening for open angle glaucoma in developed countries. Indian J Ophthalmol 2011; 59(suppl): S24-S30.
13. Tuulonen A: Economics of surgery worldwide. Developed countries; in Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG (eds): Glaucoma. Philadelphia, Saunders, 2009, pp 3-11.
14. Haymes SA, LeBlanc RP, Nicolela MT, et al: Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci 2007; 48: 1149-1155. (Pubitemid 351261409)
15. Haymes SA, LeBlanc RP, Nicolela MT, et al: Glaucoma and on-road driving performance. Invest Ophthalmol Vis Sci 2008; 49: 3035-3041.
16. Hatt S, Wormald R, Burr J: Screening for prevention of optic nerve damage due to chronic open angle glaucoma. Cochrane Database Syst Rev 2006; 4:CD006129.
17. Grødum K, Heijl A, Bengtsson B: A comparison of glaucoma patients identified through mass screening and in routine clinical practice. Acta Ophthalmol Scand 2002; 80: 627-631. (Pubitemid 36024476)
18. Reus NJ, Lemij HG, Garway-Heath DF, et al: Clinical assessment of stereoscopic optic disc photographs for glaucoma: the European Optic Disc Assessment Trial. Ophthalmology 2010; 117: 717-723.
19. Hood DC, Kardon RH: A framework for comparing structural and functional measures of glaucomatous damage. Prog Retin Eye Res 2007; 26: 688-710. (Pubitemid 47615565)
20. Weinreb RN, Zangwill LM, Jain S, et al: Predicting the onset of glaucoma: the confocal scanning laser ophthalmoscopy ancillary study to the Ocular Hypertension Treatment Study. Ophthalmology 2010; 117: 1674-1683.
21. Folio LS, Wollstein G, Schuman JS: Optical coherence tomography: future trends for imaging in glaucoma. Optom Vis Sci 2012; 89:E554-E562.
22. Gong G, Kosoko-Lasaki S, Haynatzki G, et al: Inherited, familial and sporadic primary open-angle glaucoma. J Natl Med Assoc 2007; 99: 559-563. (Pubitemid 46752734)
23. Allingham RR, Liu Y, Rhee DJ: The genetics of primary open-angle glaucoma: a review. Exp Eye Res 2009; 88: 837-844.
24. Stone EM, Fingert JH, Alward WL, et al: Identification of a gene that causes primary open angle glaucoma. Science 1997; 275: 668-670. (Pubitemid 27061334)
25. Rezaie T, Child A, Hitchings R, et al: Adultonset primary open-angle glaucoma caused by mutations in optineurin. Science 2002; 295: 1077-1079. (Pubitemid 34132238)
26. Monemi S, Spaeth G, DaSilva A, et al: Identification of a novel adult-onset primary openangle glaucoma (POAG) gene on 5q22.1. Hum Mol Genet 2005; 14: 725-733. (Pubitemid 40403270)
27. Pasutto F, Matsumoto T, Mardin CY, et al: Heterozygous NTF4 mutations impairing neurotrophin-4 signaling in patients with primary open-angle glaucoma. Am J Hum Genet 2009; 85: 447-456.
28. Vithana EN, Nongpiur ME, Venkataraman D, et al: Identification of a novel mutation in the NTF4 gene that causes primary openangle glaucoma in a Chinese population. Mol Vis 2010; 16: 1640-1645.
29. Fan BJ, Wang DY, Fan DS, et al: SNPs and interaction analyses of myocilin, optineurin, and apolipoprotein E in primary open angle glaucoma patients. Mol Vis 2005; 11: 625-631. (Pubitemid 41410212)
30. Thorleifsson G, Walters GB, Hewitt AW, et al: Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat Genet 2010; 42: 906-909.
31. Burdon KP, Macgregor S, Hewitt AW, et al: Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat Genet 2011; 43: 574-578.
32. Thorleifsson G, Magnusson KP, Sulem P, et al: Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 2007; 317: 1397-1400. (Pubitemid 47417481)
33. Ozaki M, Lee KY, Vithana EN, et al: Association of LOXL1 gene polymorphisms with pseudoexfoliation in the Japanese. Invest Ophthalmol Vis Sci 2008; 49: 3976-3980.
34. Ramprasad VL, George R, Soumittra N, et al: Association of non-synonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India. Mol Vis 2008; 14: 318-322. (Pubitemid 351279917)
35. Hayashi H, Gotoh N, Ueda Y, et al: Lysyl oxidase-like 1 polymorphisms and exfoliation syndrome in the Japanese population. Am J Ophthalmol 2008; 145: 582-585.
36. Chen L, Jia L, Wang N, et al: Evaluation of LOXL1 polymorphisms in exfoliation syndrome in a Chinese population. Mol Vis 2009; 15: 2349-2357.
37. Williams SE, Whigham BT, Liu Y, et al: Major LOXL1 risk allele is reversed in exfoliation glaucoma in a black South African population. Mol Vis 2010; 16: 705-712.
38. van Koolwijk LM, Ramdas WD, Ikram MK, et al: Common genetic determinants of intraocular pressure and primary open-angle glaucoma. PLoS Genet 2012; 8:e1002611.
39. Lee DA, Higginbotham EJ: Glaucoma and its treatment: a review. Am J Health Syst Pharm 2005; 62: 691-699. (Pubitemid 40462838)
40. Netland PA, Landry T, Sullivan EK, et al: Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-484. (Pubitemid 32904567)
41. Sherwood M, Brandt J, Bimatoprost Study Groups 1 and 2: Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001; 45(suppl 4):S361-S368.
42. Hedman K, Alm A, Gross RL: Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma 2003; 12: 463-465. (Pubitemid 37494172)
43. Tsai JC, Kanner EM: Current and emerging medical therapies for glaucoma. Expert Opin Emerg Drugs 2005; 10: 109-118. (Pubitemid 40293073)
44. Schwartz GF, Reardon G, Mozaffari E: Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004; 137(1 suppl):S13-S16. (Pubitemid 38091630)
45. Asrani S, Zeimer R, Wilensky J, et al: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-142. (Pubitemid 32441322)
46. Bergea B, Bodin L, Svedbergh B: Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 1999; 106: 997-1004.
47. Gurwitz JH, Yeomans SM, Glynn RJ, et al: Patient noncompliance in the managed care setting. The case of medical therapy for glaucoma. Med Care 1998; 36: 357-369. (Pubitemid 128456379)
48. Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C: Compliance and viewpoint of glaucoma patients in Greece. Eye (Lond) 2000; 14: 752-756.
49. Kass MA, Meltzer DW, Gordon M, et al: Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986; 101: 515-523. (Pubitemid 16114195)
50. Carassa RG, Bettin P, Fiori M, Ciampi C: Are glaucoma patients reliable in managing their therapy? Invest Ophthalmol Vis Sci 2007; 48: 5582, E-abstract.
51. Lavik E, Kuehn MH, Kwon YH: Novel drug delivery systems for glaucoma. Eye (Lond) 2011; 25: 578-586.
52. Kosoko O, Quigley HA, Vitale S, et al: Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic. Ophthalmology 1998; 105: 2105-2111. (Pubitemid 30211781)
53. Fiscella RG, Green A, Patuszynski DH, Wilensky J: Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003; 136: 18-25. (Pubitemid 36794490)
54. Gurwitz JH, Glynn RJ, Monane M, et al: Treatment for glaucoma: adherence by the elderly. Am J Public Health 1993; 83: 711-716. (Pubitemid 23143002)
55. Chen J, Runyan SA, Robinson MR: Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol 2011; 5: 667-677.
56. Zhang K, Zhang L, Weinreb RN: Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 2012; 11: 541-559.
57. Levin LA: Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Surv Ophthalmol 1999; 43(suppl 1):S98-S101. (Pubitemid 29328585)
58. Neacsu A, Oprean C, Curea M, et al: Neuroprotection with carotenoids in glaucoma (in Romanian). Oftalmologia 2003; 59: 70-75.
59. Neufeld AH: New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. J Glaucoma 1998; 7: 434-438. (Pubitemid 30247091)
60. Weinreb RN, Levin LA: Is neuroprotection a viable therapy for glaucoma? Arch Ophthalmol 1998; 117: 1540-1544. (Pubitemid 29536483)
61. Sena DF, Ramchand K, Lindsley K: Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2010; 2:CD006539.
62. Katz LJ, Steinmann WC, Kabir A, et al: Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma 2012; 21: 460-468.
63. Detry-Morel M, Muschart F, Pourjavan S: Micropulse diode laser (810 nm) versus argon laser trabeculoplasty in the treatment of open-angle glaucoma: comparative shortterm safety and efficacy profile. Bull Soc Belge Ophtalmol 2008; 308: 21-28.
64. Goldenfeld M, Melamed S, Simon G, Ben Simon GJ: Titanium:sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma. Ophthalmic Surg Lasers Imaging 2009; 40: 264-269.
65. Rachmiel R, Trope GE, Chipman ML, et al: Effect of medical therapy on glaucoma filtration surgery rates in Ontario. Arch Ophthalmol 2006; 124: 1472-1477. (Pubitemid 44537149)
66. Keenan TD, Wotton CJ, Goldacre MJ: Recent trends in the rate of trabeculectomy in England. Eye (Lond) 2011; 25: 1243-1245.
67. Baudouin C: Ocular surface and external filtration surgery: mutual relationships. Dev Ophthalmol 2012; 50: 64-78.
68. Holló G: Wound healing and glaucoma surgery: modulating the scarring process with conventional antimetabolites and new molecules. Dev Ophthalmol 2012; 50: 79-89.
69. European Glaucoma Society: Terminology and Guidelines for Glaucoma, ed 3. 2009.
70. American Academy of Ophthalmology: Primary Open-Angle Glaucoma, Preferred Practice Pattern. San Francisco, American Academy of Ophthalmology, 2005, pp 15-16.
71. Lin SC: Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma. J Glaucoma 2008; 17: 238-247. (Pubitemid 351543551)
72. Kosoko O, Gaasterland DE, Pollack IP, Enger CL: Long-term outcome of initial ciliary ablation with contact diode laser transscleral cyclophotocoagulation for severe glaucoma. The Diode Laser Ciliary Ablation Study Group. Ophthalmology 1996; 103: 1294-1302. (Pubitemid 26282514)
73. Rotchford AP, Jayasawal R, Madhusudhan S, et al: Transscleral diode laser cycloablation in patients with good vision. Br J Ophthalmol 2012; 94: 1180-1183.
74. Tan AM, Chockalingam M, Aquino MC, et al: Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma. Clin Experiment Ophthalmol 2010; 38: 266-272.
75. Khaw PT, Chiang M, Shah P, et al: Enhanced trabeculectomy: the Moorfields safer surgery system. Dev Ophthalmol 2012; 50: 1-28.
76. Rotchford AP, King AJ: Moving the goal posts definitions of success after glaucoma surgery and their effect on reported outcome. Ophthalmology 2010; 117: 18-23.
77. Shuster JN, Krupin T, Kolker AE, Becker B: Limbus-v fornix-based conjunctival flap in trabeculectomy. A long-term randomized study. Arch Ophthalmol 1984; 102: 361-362. (Pubitemid 14197281)
78. Wells AP, Cordeiro MF, Bunce C, Khaw PT: Cystic bleb formation and related complications in limbus-versus fornix-based conjunctival flaps in pediatric and young adult trabeculectomy with mitomycin C. Ophthalmology 2003; 110: 2192-2197. (Pubitemid 37337858)
79. Papaconstantinou D, Georgalas I, Karmiris E, et al: Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: a pilot study. Acta Ophthalmol 2010; 88: 80-85.
80. Stalmans I, Gillis A, Lafaut AS, Zeyen T: Safe trabeculectomy technique: long-term outcome. Br J Ophthalmol 2006; 90: 44-47. (Pubitemid 43029895)
81. Shah P, Agrawal P, Khaw PT, et al: ReGAE 7: long-term outcomes of augmented trabeculectomy with mitomycin C in African-Caribbean patients. Clin Experiment Ophthalmol 2012; 40:e176-e182.
82. Prasad N, Latina MA: Blebitis and endophthalmitis after glaucoma filtering surgery. Int Ophthalmol Clin 2007; 47: 85-97. (Pubitemid 46725806)
83. Ciulla TA, Beck AD, Topping TM, Baker AS: Blebitis, early endophthalmitis, and late endophthalmitis after glaucoma filtering surgery. Ophthalmology 1997; 104: 986-995. (Pubitemid 27255411)
84. De Jong L, Lafuma A, Aguadé AS, Berdeaux G: Five-year extension of a clinical trial comparing the Ex-PRESS glaucoma filtration device and trabeculectomy in primary open-angle glaucoma. Clin Ophthalmol 2011; 5: 527-533.
85. Sugiyama T, Shibata M, Kojima S, et al: The first report on intermediate-term outcome of Ex-PRESS glaucoma filtration device implanted under scleral flap in Japanese patients. Clin Ophthalmol 2011; 5: 1063-1066.
86. Bissig A, Rivier D, Zaninetti M, et al: Ten years follow-up after deep sclerectomy with collagen implant. J Glaucoma 2008; 17: 680-686.
87. Cheng JW, Cheng SW, Cai JP, et al: Systematic overview of the efficacy of nonpenetrating glaucoma surgery in the treatment of open angle glaucoma. Med Sci Monit 2011; 17: 155-163.
88. Geffen N, Assia EI, Melamed S: Laser-assisted techniques for penetrating and nonpenetrating glaucoma surgery. Dev Ophthalmol 2012; 50: 96-108.
89. 2 laser-assisted sclerectomy surgery, part II: multicenter clinical preliminary study. J Glaucoma 2012; 21: 193-198.
90. Gedde SJ, Schiffman JC, Feuer WJ, et al: Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol 2012; 153: 789-803.
91. Gedde SJ, Herndon LW, Brandt JD, et al: Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol 2012; 153: 804-814.
92. Kobayashi H, Kobayashi K: Randomized comparison of the intraocular pressure-lowering effect of phacoviscocanalostomy and phacotrabeculectomy. Ophthalmology 2007; 114: 909-914. (Pubitemid 46635851)
93. Carassa RG, Bettin P, Fiori M, Brancato R: Viscocanalostomy versus trabeculectomy in white adults affected by open-angle glaucoma: a 2-year randomized, controlled trial. Ophthalmology 2003; 110: 882-887. (Pubitemid 36560483)
94. Gilmour DF, Manners TD, Devonport H, et al: Viscocanalostomy versus trabeculectomy for primary open angle glaucoma: 4-year prospective randomized clinical trial. Eye (Lond) 2009; 23: 1802-1807.
95. Peckar CO, Koerber N: Canaloplasty for open angle glaucoma: a three-year critical evaluation and comparison with viscocanalostomy. Spektrum Augenheilkd 2008; 22: 240-246.
96. Lewis RA, von Wolff K, Tetz M, et al: Canaloplasty: three-year results of circumferential viscodilation and tensioning of Schlemm canal using a micro catheter to treat open-angle glaucoma. J Cataract Refract Surg 2011; 37: 682-690.
97. Grieshaber MC, Pienaar A, Olivier J, Stegmann R: Canaloplasty for primary open-angle glaucoma: long-term outcome. Br J Ophthalmol 2010; 94: 1478-1482.
98. Francis BA, Winarko J: Ab interno Schlemm's canal surgery: Trabectome and iStent. Dev Ophthalmol 2012; 50: 125-136.
99. Samuelson TW, Katz LJ, Wells JM, et al: Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology 2011; 118: 459-467.
100. Camras LJ, Yuan F, Fan S, et al: A novel Schlemm's Canal scaffold increases outflow facility in a human anterior segment perfusion model. Invest Ophthalmol Vis Sci 2012; 53: 6115-6121.
101. Samuelson TW, Pfeiffer N, Lorenz K: Sixmonth results from a prospective, multicenter study of a nickel-titanium Schlemm's canal scaffold for IOP reduction in open-angle glaucoma. 22nd Annual AGS Meeting, New York, March 2012.
102. Hoeh H, Ahmed II, Grisanti S, et al: Early postoperative safety and surgical outcomes after implantation of a suprachoroidal micro-stent for the treatment of open-angle glaucoma concomitant with cataract surgery. J Cataract Refract Surg 2013; 39: 431-437.
103. Mosaed S, Rhee DJ, Filippopoulos T, et al: Trabectome outcomes in adult open-angle glaucoma patients: one year follow-up. Clin Surg Ophthalmol 2010; 28: 5-9.
104. Jea SY, Francis BA, Vakili G, et al: Ab interno trabeculectomy versus trabeculectomy for open-angle glaucoma. Ophthalmology 2012; 119: 36-42.
105. Jea SY, Mosaed S, Vold SD, Rhee DJ: Effect of a failed Trabectome on subsequent trabeculectomy. J Glaucoma 2012; 21: 71-75.
106. Babighian S, Caretti L, Tavolato M, et al: Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye (Lond) 2010; 24: 632-638.